Immix Biopharma initiated with an Outperform at Mizuho

Mizuho analyst Graig Suvannavejh initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $14 price target which implies 108% upside potential. With no approved therapies for refractory/relapsed light chain amyloidosis, Immix is advancing NXC-201, a novel BCMA-directed CAR-T, the analyst tells investors in a research note. The firm views NXC-201 as “meaningfully de-risked” following the positive Phase 1 and Phase 2 data sets and its “encouraging” key opinon leader feedback.